188.86MMarket Cap-1583P/E (TTM)
2.140High2.016Low633.33KVolume2.070Open2.080Pre Close1.32MTurnover0.78%Turnover RatioLossP/E (Static)90.36MShares8.33052wk High0.61P/B170.25MFloat Cap1.50052wk Low--Dividend TTM81.46MShs Float32.645Historical High--Div YieldTTM5.96%Amplitude1.500Historical Low2.079Avg Price1Lot Size
Caribou Biosciences Stock Forum
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
No comment yet